{
  "docId": "019de075-e6e6-7212-9fa1-8acb312e82f0",
  "docSlug": "a6ecebb143ed44be24e72b777fff8cb3",
  "documentTitle": "argenx SE | Results Presentation Deck | 14 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 14,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a timeline-based clinical trial design framework.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-e6e6-7212-9fa1-8acb312e82f0/5",
  "deckHref": "/decks/019de075-e6e6-7212-9fa1-8acb312e82f0",
  "deckJsonHref": "/decks/019de075-e6e6-7212-9fa1-8acb312e82f0.json",
  "deckAnchorHref": "/decks/019de075-e6e6-7212-9fa1-8acb312e82f0#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.44,
        "x": 0.28,
        "y": 0.84
      },
      "kind": "callout",
      "text": "Topline data expected 4Q 2023",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2844b70c-ad6f-4f97-9b46-2bf29596e0de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.71,
        "x": 0.26,
        "y": 0.32
      },
      "kind": "diagram",
      "text": "Patients randomized 2:1 to receive VYVGART Hytrulo or placebo (24 weeks). Fixed weekly dosing, Weekly or q2w dosing based on platelet count thresholds, Fixed weekly or q2w dosing based on week 15.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca35cf69-f415-4991-b4ab-65921409924f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.15,
        "x": 0.79,
        "y": 0.02
      },
      "kind": "image",
      "text": "advance SC immune thrombocytopenia study",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8398e7a-08cf-4514-98ec-4014c4760db9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.22,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "list",
      "text": "Adult Chronic or Persistent ITP patients; 2 weeks screening; Mean platelet count <30x10^9/L; Stable concomitant ITP therapy allowed; Stratification: splenectomy, concomitant ITP therapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e3c7fd0-6a7d-462d-8e90-4c0ee6ce4d7f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.15,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "Primary endpoint: Sustained platelet count (≥50x10^9/L) in ≥4/6 visits between weeks 19 and 24. Stringent endpoint in line with regulatory feedback, addressing platelet count variability. Secondary and exploratory endpoints center around extent of disease control to illustrate real-world viability",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf5f74b7-03a7-4024-bcf1-7cd87d39b79b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.25,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "ITP ADVANCE-SC Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27bb1971-19e0-4eb6-b90f-4ad075450473",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "b18ec4cc-5495-48a3-9dd9-5decd45ab308",
      "evidence": "Primary endpoint: Sustained platelet count (≥50x10^9/L) in ≥4/6 visits between weeks 19 and 24.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "20cfc2f1-7f91-4a81-ab9a-3bdd3633753a",
      "evidence": "Timeline visualization of clinical trial phases and dosing schedule",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}